» Articles » PMID: 24009455

Encapsulating Peritoneal Sclerosis: Case Series from a University Center

Overview
Specialty General Medicine
Date 2013 Sep 7
PMID 24009455
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Encapsulating peritoneal sclerosis (EPS) is an often-fatal complication of long-term peritoneal dialysis (PD). We here report the clinical features of EPS in Korean PD patients from a single university center.

Methods: The data were collected retrospectively from 606 PD patients at Kyungpook National University Hospital, between August 2001 and August 2011. The diagnosis of EPS was based on clinical signs and symptoms, and confirmed by radiological findings.

Results: Eight patients (1.3%, four males) were diagnosed with EPS. The mean age of the patients was 48.5 years (range, 33 to 65). The mean duration of PD was 111.8 months (range, 23 to 186). All patients except for one had three or more episodes of peritonitis. Seven patients were diagnosed with EPS after stopping PD, and only one stayed on PD after initial diagnosis and treatment. Total parenteral nutrition and corticosteroids, in addition to tamoxifen therapy, were used to treat most of the patients, and one patient underwent surgery (adhesiolysis). The overall mortality rate was 50%.

Conclusions: EPS is a serious, life-threatening complication in patients on long-term PD. To reduce the incidence and mortality rate of EPS, careful monitoring and early diagnosis is needed.

Citing Articles

Encapsulating Peritoneal Sclerosis: A Case Report and Literature Review.

Al-Lawati A, Al Shaibi M, Al Mahruqi G, Augustine T, Moinuddin Z, Al Hinai M Am J Case Rep. 2020; 21:e925341.

PMID: 33011732 PMC: 7545366. DOI: 10.12659/AJCR.925341.


Outcomes of the surgical management of encapsulating peritoneal sclerosis: A case series from a single center in Korea.

Ryu J, Lee K, Koo T, Kim D, Oh K, Yang J Kidney Res Clin Pract. 2019; 38(4):499-508.

PMID: 31640301 PMC: 6913596. DOI: 10.23876/j.krcp.19.044.


A case of acute EPS with local cocoon formation in a patient on peritoneal dialysis.

Cavoli G, Tralongo A, Ferrantellii A, Li Cavoli T, Tralongo P, Ferrantelli G CEN Case Rep. 2017; 4(2):243-245.

PMID: 28509109 PMC: 5413774. DOI: 10.1007/s13730-015-0178-x.


Combined surgical and immunosupressive therapy for encapsulating peritoneal sclerosis.

Bipi P, Gracious N, Kumar S, George J Indian J Nephrol. 2016; 26(6):458-460.

PMID: 27942181 PMC: 5131388. DOI: 10.4103/0971-4065.177139.


Sclerosing Encapsulating Peritonitis: Review.

Machado N Sultan Qaboos Univ Med J. 2016; 16(2):e142-51.

PMID: 27226904 PMC: 4868512. DOI: 10.18295/squmj.2016.16.02.003.


References
1.
Habib A, Preston E, Davenport A . Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription. Nephrol Dial Transplant. 2009; 25(5):1633-8. DOI: 10.1093/ndt/gfp677. View

2.
Kocianova S, Vuong C, Yao Y, Voyich J, Fischer E, DeLeo F . Key role of poly-gamma-DL-glutamic acid in immune evasion and virulence of Staphylococcus epidermidis. J Clin Invest. 2005; 115(3):688-94. PMC: 546460. DOI: 10.1172/JCI23523. View

3.
Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos D . Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int. 2000; 20 Suppl 4:S43-55. View

4.
Kyuden Y, Ito T, Masaki T, Yorioka N, Kohno N . Tgf-beta1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int. 2005; 25(5):483-91. View

5.
Balasubramaniam G, Brown E, Davenport A, Cairns H, Cooper B, Fan S . The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant. 2009; 24(10):3209-15. DOI: 10.1093/ndt/gfp008. View